Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Armenia
Ophthalmological Center After S.V.Malayan, Yerevan Israel
Sharei Zedek Medical Center, Jerusalem, Jerusalem Rambam Medical Center, Haifa